Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Enzymatica AB: BioStock: Enzymatica's CEO comments on promising in-vitro data for ColdZyme

Enzymatica

Enzymatica presents positive results from an in-vitro study at Medical University of Innsbruck. The results show that ColdZyme breaks the viral infection cycle and significantly reduces the viral load in human cells infected with influenza A. Enzymatica's CEO Claus Egstrand visited BioStock's studio to talk about ColdZyme and the study results. 

Watch the interview at biostock.se:

https://www.biostock.se/en/2023/08/enzymaticas-ceo-comments-on-promising-in-vitro-data-for-coldzyme/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.